Login
Companies $RCUS
$16.86 +$0.00 (0.0%) After hours
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

arcusbio.com

What Do They Do?

Develops drug candidates for cancer and inflammatory and autoimmune diseases, and licenses programs to pharmaceutical partners.

How Do They Make Money?

Partners pay Arcus for program licenses, research and development, and clinical materials through upfront fees and milestones; service revenue is earned as work is performed, and royalties can be tied to licensed-product sales.

revenue
SegmentShareRevenue
License and development services
Licensed

89%
Other Collaboration Revenue
11%
FY2022: 34%

Who Are Their Customers?

Arcus works through license and collaboration agreements with pharmaceutical partners: Gilead holds licenses to cancer programs, while Taiho has regional rights to several programs. Arcus also co-develops selected programs with Gilead.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 96% from one customer

Do Revenues Turn Into Profits?

No. It lost $353M in FY2025.

Operating income, FY2025
−156% of revenue
▼ −17% (Loss) vs FY2024 (−$330M, −128%)
Net income, FY2025
−143% of revenue
▼ −25% (Loss) vs FY2024 (−$283M, −110%)
Free cash flow, FY2025
−196% of revenue
▼ −175% (Loss) vs FY2024 (−$176M, −68%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −65%
vs $26M in Q3 FY2025
Net income
▲ +5% (Loss)
vs −$135M in Q3 FY2025
License and development services share of revenue vs 76.9% in Q3 FY2025
  • Apr 20, 2026 Gilead will end options to additional early-stage programs After Gilead declined a continuation payment, its options to additional programs will end; existing time-limited program options remain.

Shrinking. Revenue fell 36% in 4 years, from $383M in FY2021 to $247M in FY2025, about 10% a year.

A broader research focus The older report centered its oncology portfolio on domvanalimab and zimberelimab combinations. The latest report foregrounds casdatifan studies in kidney cancer and describes inflammation and autoimmune discovery programs using small molecules.

Revenue over time
License and development services Other Collaboration Revenue License and Development Services Revenue
$500M$250M$0

Who Do They Compete With?

Competes with AstraZeneca, BeiGene, Bristol-Myer Squibb, Merck, Novartis, Pfizer, Regeneron, Sanofi, Roche/Genentech, Celldex Therapeutics, Abbvie, Amgen, NiKang Therapeutics, Arrowhead Pharmaceuticals, I-MAB Biopharma, Incyte, Innate Pharma, Innovent Biologics, Antengene, and ORIC Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support